Transplantation for hilar cholangiocarcinoma

Liver Transplantation

Volumn 10, Issue 10 SUPPL. 2, 2004, Pages

  Heimbach, Julie K ^a   Haddock, Michael G ^a   Alberts, Steven R ^a   Nyberg, Scott L ^a   Ishitani, Michael B ^a   Rosen, Charles B ^a   Gores, Gregory J ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; FLUOROURACIL; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; PREDNISONE; TACROLIMUS;

ADULT; ANEUPLOIDY; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT SURGERY; CANCER DIAGNOSIS; CANCER RISK; CANCER SURGERY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DIGITAL RADIOGRAPHY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMAGE ANALYSIS; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; CLINICAL PROTOCOLS; HEALTH CARE RATIONING; HUMANS; LIVER TRANSPLANTATION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 6944252082     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20266     Document Type: Article

References (10)

1. Gores GJ. Cholangiocarcinoma: current concepts and insights. Hepatology 2003;37:961-969.
2. Rosen CB, Nagorney DM. Cholangiocarcinoma complicating primary sclerosing cholangitis. Semin Liver Dis 1991;11:26-30.
3. Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Loof L, Danielsson A, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002;36:321-327.
4. Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BJ, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001;234: 507-517; discussion 517-509.
5. Shimoda M, Farmer DG, Colquhoun SD, Rosove M, Ghobrial RM, Yersiz H, et al. Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature. Liver Transpl 2001;7:1023-1033.
6. Foo ML, Gunderson LL, Bender CE, Buskirk SJ. External radiation therapy and transcatheter iridium in the treatment of extra-hepatic bile duct carcinoma. Int J Radiat Oncol Biol Phys 1997; 39:929-935.
7. De Vreede I, Steers JL, Burch PA, Rosen CB, Gunderson LL, Haddock MG, et al. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl 2000;6:309-316.
8. Sudan D, DeRoover A, Chinnakotla S, Fox I, Shaw B, Jr, McCashland T, et al. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant 2002;2:774-779.
9. Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004;99:523-526.
10. Brandsaeter B, Isoniemi H, Broome U, Olausson M, Backman L, Hansen B, et al. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol 2004;40:815-822.